Non-cholinergic strategies for treating and preventing Alzheimer's disease.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  CNS Drugs

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2165/00023210-200216120-00003PMID 12421115
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cholinesterase Inhibitors for Alzheimer’s Disease

  2012cited by this paper
• Neuroprotective and symptomatological action of memantine relevant for alzheimer’s disease — a unified glutamatergic hypothesis on the mechanism of action

  2009cited by this paper
• Ensaculin (KA-672 HCl): a multitransmitter approach to dementia treatment.

  2006cited by this paper
• Rapid appearance of β-amyloid precursor protein immunoreactivity in glial cells follwing excitotoxic brain injury

  2004cited by this paper
• Donepezil in the treatment of Alzheimer's disease: long-term efficacy and safety.

  2002cited by this paper
• Teaching old rats new tricks: age-related impairments in olfactory reversal learning.

  2002cited by this paper
• Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease

  2002cited by this paper
• A Case-Control Analysis of Nonsteroidal Anti-Inflammatory Drugs and Alzheimer’s Disease: Are They Protective?

  2002cited by this paper
• Effects of estrogen treatment on glutamate uptake in cultured human astrocytes derived from cortex of Alzheimer's disease patients

  2002cited by this paper
• Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs.

  2002cited by this paper
• Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people.

  2002cited by this paper
• Neuroimaging and geriatric psychiatry in the new millennium: the promise, the reality, and the need for more integrated approaches.

  2002cited by this paper
• Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

  2002cited by this paper
• Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid.

  2002cited by this paper
• Plasma homocysteine as a risk factor for dementia and Alzheimer's disease.

  2002cited by this paper
• Ginkgo for memory enhancement: a randomized controlled trial.

  2002cited by this paper
• Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. Writing Group for the Women's Health Initiative Investigators. JAMA 2002; 288(3): 321-333

  2002cited by this paper
• Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent

  2002cited by this paper
• Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer's disease?

  2001cited by this paper
• Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease.

  2001cited by this paper
• A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

  2001cited by this paper
• Simvastatin‐Associated Memory Loss

  2001cited by this paper
• Galantamine: a randomized, double‐blind, dose comparison in patients with Alzheimer's disease

  2001cited by this paper
• Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics

  2001cited by this paper
• Treatment of Alzheimer’s Disease with Clioquinol

  2001cited by this paper
• Neuropsychological changes after 30-day Ginkgo biloba administration in healthy participants.

  2001cited by this paper
• Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo

  2001cited by this paper
• Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

  2001cited by this paper
• New approaches to diagnose and treat Alzheimer's disease: a glimpse of the future.

  2001cited by this paper
• Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo.

  2001cited by this paper
• A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease

  2001cited by this paper
• A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

  2001cited by this paper
• Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice

  2001cited by this paper
• A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD

  2001cited by this paper
• Pravastatin Improves Cerebral Vasomotor Reactivity in Patients With Subcortical Small-Vessel Disease

  2001cited by this paper
• [A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia].

  2001cited by this paper
• A Double‐Blind, Placebo‐Controlled, Multicenter Study of Cerebrolysin for Alzheimer's Disease

  2000cited by this paper
• Prospects for pharmacological intervention in Alzheimer disease.

  2000cited by this paper
• Statins and the risk of dementia.

  2000cited by this paper
• Cholinesterase inhibitors and Gingko extracts--are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months' duration.

  2000cited by this paper
• The Efficacy of Ginkgo for Elderly People with Dementia and Age‐Associated Memory Impairment: New Results of a Randomized Clinical Trial

  2000cited by this paper
• Estrogen for Alzheimer’s disease in women

  2000cited by this paper
• Effects of estrogen on cognition, mood, and cerebral blood flow in AD

  2000cited by this paper
• Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy

  2000cited by this paper
• Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains.

  2000cited by this paper
• Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists

  2000cited by this paper
• NMDA channel blockers: memantine and amino-aklylcyclohexanes –In vivo characterization

  2000cited by this paper
• Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

  2000cited by this paper
• Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study.

  2000cited by this paper
• Glial Modulating and Neurotrophic Properties of Propentofylline and Its Application to Alzheimer's Disease and Vascular Dementia

  2000cited by this paper
• Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model.

  2000cited by this paper
• Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial

  2000cited by this paper
• Cholinesterase inhibitors and Ginkgo extracts — are they comparable in the treatment of dementia?

  2000cited by this paper
• Histochemically Reactive Zinc in Plaques of the Swedish Mutant β-Amyloid Precursor Protein Transgenic Mice

  1999cited by this paper
• Aqueous Dissolution of Alzheimer’s Disease Aβ Amyloid Deposits by Biometal Depletion*

  1999cited by this paper
• A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease

  1999cited by this paper
• Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study.

  1999cited by this paper
• Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data.

  1999cited by this paper
• Defining Meaningful Change in Alzheimer's Disease Trials: The Donepezil Experience

  1999cited by this paper
• Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

  1999cited by this paper
• Probable Alzheimer's disease: gender-related issues.

  1999cited by this paper
• Oxidative Alterations in Alzheimer's Disease

  1999cited by this paper
• Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization.

  1999cited by this paper
• Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.

  1998cited by this paper
• Vitamin E and Vitamin C Supplement Use and Risk of Incident Alzheimer Disease

  1998cited by this paper
• Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease

  1998cited by this paper
• Identification of Cognitive Impairment in the Elderly: Homocysteine Is an Early Marker

  1998cited by this paper
• Total serum homocysteine in senile dementia of Alzheimer type

  1998cited by this paper
• The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease.

  1998cited by this paper
• Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging

  1998cited by this paper
• A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease

  1998cited by this paper
• Cohort study of vitamin C intake and cognitive impairment.

  1998cited by this paper
• Copper, iron and zinc in Alzheimer's disease senile plaques.

  1998cited by this paper
• Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.

  1997cited by this paper
• Risk of Alzheimer's disease and duration of NSAID use

  1997cited by this paper
• Estrogen, cognition, and a woman's risk of Alzheimer's disease.

  1997cited by this paper
• The role of estrogen in the treatment and prevention of dementia: introduction.

  1997cited by this paper
• Iron accumulation in Alzheimer disease is a source of redox-generated free radicals.

  1997cited by this paper
• The Alzheimer's disease assessment scale

  1997cited by this paper
• Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies.

  1997cited by this paper
• Acetylcholine, aging, and Alzheimer's disease.

  1997cited by this paper
• A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

  1997cited by this paper
• Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease.

  1996cited by this paper
• Learning deficits induced by chronic intraventricular infusion of quinolinic acid--protection by MK-801 and memantine.

  1996cited by this paper
• Amyloid β Peptide (25–35) Inhibits Na+‐Dependent Glutamate Uptake in Rat Hippocampal Astrocyte Cultures

  1996cited by this paper
• Apparent independent action of nimodipine and glutamate antagonists to protect cultured neurons against glutamate-induced damage.

  1996cited by this paper
• Anti‐Inflammatory Drugs in the Fight against Alzheimer's Disease a

  1996cited by this paper
• Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease

  1996cited by this paper
• β‐Amyloid peptide fragment 25–35 potentiates the calcium‐dependent release of excitatory amino acids from depolarized hippocampal slices

  1995cited by this paper
• Aging, energy, and oxidative stress in neurodegenerative diseases

  1995cited by this paper
• Rapid appearance of beta-amyloid precursor protein immunoreactivity in glial cells following excitotoxic brain injury.

  1995cited by this paper
• Microglial release of nitric oxide by the synergistic action of β-amyloid and IFN-γ

  1995cited by this paper
• Are reactive oxygen species involved in Alzheimer's disease?

  1995cited by this paper
• The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases.

  1995cited by this paper
• Microglial release of nitric oxide by the synergistic action of beta-amyloid and IFN-gamma.

  1995cited by this paper
• Nonsteroidal anti-inflammatory drugs in Alzheimer's disease

  1995cited by this paper
• MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis.

  1995cited by this paper
• Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat.

  1994cited by this paper
• Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT).

  1994cited by this paper
• Estrogen deficiency and risk of Alzheimer's disease in women.

  1994cited by this paper

• Low Intake of Total Antioxidant Nutrients as a Risk Factor for Incident Dementia in Older Adults: The Shanghai Aging Study

  2024cites this paper
• New Sulfonate Ester‐Linked Fluorinated Hydrazone Derivatives as Multitarget Carbonic Anhydrase and Cholinesterase Inhibitors: Design, Synthesis, Biological Evaluation, Molecular Docking and ADME Analysis

  2024cites this paper
• The Link Between Alzheimer's Disease and Stroke: A Detrimental Synergism.

  2024cites this paper
• Synthesis, Characterization, and MAO Inhibitory Activities of Three New Drug-like N-Acylhydrazone Derivatives

  2024cites this paper
• High-dose Agomelatine Combined with Haloperidol Decanoate Improves Cognition, Downregulates MT2, Upregulates D5, and Maintains Krüppel-like Factor 9 But Alters Cardiac Electrophysiology

  2024cites this paper
• The Potent and Selective Histamine H3 Receptor Antagonist E169 Counteracts Cognitive Deficits and Mitigates Disturbances in the PI3K/AKT/GSK-3β Signaling Pathway in MK801-Induced Amnesia in Mice

  2023cites this paper
• Alzheimer's Disease and Stroke: A Tangled Neurological Conundrum

  2022influential citation
• The relationship between nutrition and the immune system

  2022cites this paper
• Evaluation of selected carotenoids of Lycopersicon esculentum variants as therapeutic targets for ‘Alzheimer’s disease: an in silico approach

  2021cites this paper
• Exploring the Mechanisms Underlying the Therapeutic Effect of Xixin Decoction on Alzheimer's Disease Based on Network Pharmacology and Molecular Docking

  2021cites this paper
• Multivariate genome wide association and network analysis of subcortical imaging phenotypes in Alzheimer’s disease

  2020cites this paper
• Early Diagnosis and Targeted Treatment Strategy for Improved Therapeutic Outcomes in Alzheimer's Disease.

  2020cites this paper
• Reviews on New Drug Targets in Age-Related Disorders

  2020cites this paper
• The Impact of New Biomarkers and Drug Targets on Age-Related Disorders.

  2020cites this paper
• Neural stem cell-conditioned medium ameliorates Aβ25–35-induced damage in SH-SY5Y cells by protecting mitochondrial function

  2020cites this paper
• Potential Pharmacokinetic Drug–Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist

  2019cites this paper
• Early Detection and Treatment of Patients with Alzheimer's Disease: Future Perspectives.

  2019cites this paper
• WS-5 Extract of Curcuma longa, Chaenomeles sinensis, and Zingiber officinale Contains Anti-AChE Compounds and Improves β-Amyloid-Induced Memory Impairment in Mice

  2019cites this paper
• Neuroprotection Afforded by a Preventive CogniXtra Treatment Against Amyloid Beta Aβ25-35 Peptide-induced Toxicity in Mice

  2019cites this paper
• Chronic memantine decreases nicotine self-administration in rats.

  2019cites this paper
• Scientific Basis for Ayurvedic Medicinal Plants Against Alzheimer’s Disease

  2019cites this paper
• Plants with evidence-based therapeutic effects against neurodegenerative diseases

  2019cites this paper
• Scientific Basis of Ayurvedic Medicine: In Hunt for a Cure to Alzheimer’s Disease

  2019cites this paper
• The Histamine H3 Receptor Antagonist DL77 Ameliorates MK801-Induced Memory Deficits in Rats

  2018cites this paper
• Molecular Pathogenesis of Alzheimer's Disease: An Update

  2017cites this paper
• Mitochondrial involvement in memory impairment induced by scopolamine in rats

  2017cites this paper
• Retinal changes in the Tg-SwDI mouse model of Alzheimer's disease.

  2017cites this paper
• Pyridoxine-resveratrol hybrids Mannich base derivatives as novel dual inhibitors of AChE and MAO-B with antioxidant and metal-chelating properties for the treatment of Alzheimer's disease.

  2017cites this paper
• Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis

  2017cites this paper
• The Histamine H3 Receptor Antagonist E159 Reverses Memory Deficits Induced by Dizocilpine in Passive Avoidance and Novel Object Recognition Paradigm in Rats

  2017cites this paper
• Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.

  2017cites this paper
• Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders.

  2017cites this paper
• Natural products against Alzheimer's disease: Pharmaco-therapeutics and biotechnological interventions.

  2017cites this paper
• Evaluation of cognition enhancing activity of pioglitazone in albino mice

  2017cites this paper
• Melatonin as a versatile molecule to design novel multitarget hybrids against neurodegeneration.

  2017cites this paper
• SOD3 Ameliorates Aβ25–35-Induced Oxidative Damage in SH-SY5Y Cells by Inhibiting the Mitochondrial Pathway

  2016cites this paper
• Vaccination to Alzheimer Disease. Is it a Promising Tool or a Blind Way?

  2016cites this paper
• Olfactory Ensheathing Cell-Conditioned Medium Reverts Aβ25–35-Induced Oxidative Damage in SH-SY5Y Cells by Modulating the Mitochondria-Mediated Apoptotic Pathway

  2016cites this paper
• The dual-acting AChE inhibitor and H3 receptor antagonist UW-MD-72 reverses amnesia induced by scopolamine or dizocilpine in passive avoidance paradigm in rats.

  2016cites this paper
• Drug-induced neurotoxicity in addiction medicine: From prevention to harm reduction.

  2016cites this paper
• The dual-acting H3 receptor antagonist and AChE inhibitor UW-MD-71 dose-dependently enhances memory retrieval and reverses dizocilpine-induced memory impairment in rats.

  2016cites this paper
• SOD3 Ameliorates H2O2-Induced Oxidative Damage in SH-SY5Y Cells by Inhibiting the Mitochondrial Pathway

  2016cites this paper
• Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease.

  2016cites this paper
• Protective role of caffeic acid in an Aβ25-35-induced Alzheimer's disease model

  2015cites this paper
• The pharmacological management of Alzheimer's disease

  2015cites this paper
• Cyclic acyl guanidines bearing carbamate moieties allow potent and dirigible cholinesterase inhibition of either acetyl- or butyrylcholinesterase.

  2014cites this paper
• SYNTHESIS, CHARACTERIZATION AND EVALUATION OF SOME POTENT MEMORY ENHANCING AGENTS DERIVED FROM P- CRESOL

  2014cites this paper
• Exploring anti-acetylcholinesterase, antioxidant and metal chelating activities of extracts of Moringa oleifera L. for possible prevention and cure of Alzheimers disease

  2014cites this paper
• Ginkgo biloba extract for dementia: a systematic review

  2013cites this paper
• Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes

  2013cites this paper
• Assessment of Therapeutic Potential of Amantadine in Methamphetamine Induced Neurotoxicity

  2013cites this paper
• Synthesis and anticholinesterase activity of fumaramide derivatives

  2013cites this paper
• Synthesis and biological evaluation of 1, 3-dihydroxyxanthone mannich base derivatives as anticholinesterase agents

  2013cites this paper
• The multifactorial nature of Alzheimer's disease for developing potential therapeutics.

  2013cites this paper
• Metal dyshomeostasis and oxidative stress in Alzheimer's disease.

  2013cites this paper
• Memantine

  2012cites this paper
• Efficacy of rivastigmine in comparison to ginkgo for treating Alzheimer's dementia.

  2012cites this paper
• Synthesis and Biological Evaluation of 3‐thiazolocoumarinyl Schiff‐base Derivatives as Cholinesterase Inhibitors

  2012cites this paper
• In vitro effect of selected medicinal plants on β-amyloid induced toxicity in neuroblastoma cells

  2012cites this paper
• Drug Treatments in Development for Alzheimer's Disease

  2012cites this paper
• TH-9 (a theophylline derivative) induces long-lasting enhancement in excitatory synaptic transmission in the rat hippocampus that is occluded by frequency-dependent plasticity in vitro.

  2012cites this paper
• Anticholinesterase of essential oils and their constituents from Thai medicinal plants on purified and cellular enzymes

  2012cites this paper
• Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases.

  2011cites this paper
• Dietary Supplementation With the Omega-3 Fatty Acid Docosahexaenoic Acid in Traumatic Brain Injury

  2011cites this paper
• commentary can Ginkgo Biloba combat Diseases

  2011cites this paper
• Alzheimer's disease and related neurodegenerative disorders: implication and counteracting of melatonin

  2011cites this paper
• Challenging behaviour and treatment for dementia

  2011cites this paper
• Inhibitory effect of Lavandula viridis on Fe(2+)-induced lipid peroxidation, antioxidant and anti-cholinesterase properties.

  2011cites this paper
• EXPLORING NOVEL TREATMENT OPTIONS: COGNITIVE DECLINE IN ALZHEIMER'S DISEASE

  2010cites this paper
• Approaches to Amyloid Therapies for the Treatment of Alzheimer's Disease

  2010cites this paper
• L-Methylfolate, Methylcobalamin, and N-Acetylcysteine in the Treatment of Alzheimer's Disease-Related Cognitive Decline

  2010cites this paper
• The pharmacological management of Alzheimer's disease

  2010cites this paper
• Investigation into the in vivo effects of five novel tacrine/ferulic acid and β-carboline derivatives on scopolamine-induced cognitive impairment in rats using radial maze paradigm

  2010cites this paper
• Beta amyloid aggregation inhibitors: small molecules as candidate drugs for therapy of Alzheimer's disease.

  2010cites this paper
• Oral health in Alzheimer's disease: a review.

  2010cites this paper
• Plants as Potential Sources for Drug Development against Alzheimer ’ s Disease

  2009influential citation
• Tacrine–Melatonin Hybrids as Multifunctional Agents for Alzheimer's Disease, with Cholinergic, Antioxidant, and Neuroprotective Properties

  2009cites this paper
• Anti-Inflammatory Properties of Acetylcholinesterase Inhibitors Administred in Alzheimers Disease

  2009cites this paper
• Can ginkgo biloba combat diseases?

  2009cites this paper
• Neuroprotection against Methamphetamine Induced Neurotoxicity: Applications for Parkinson’s Disease

  2009cites this paper
• Methamphetamine-induced neurotoxicity: the road to Parkinson’s disease

  2009cites this paper
• Memory-enhancing drugs: a molecular perspective.

  2009cites this paper
• Neurobiology of Alzheimer's disease

  2009cites this paper
• The role of adenosine system in the memantine-induced motor activity in mice

  2009cites this paper
• Oxidative stress in neurodegeneration and available means of protection.

  2008cites this paper
• Design, synthesis, and acetylcholinesterase inhibitory activity of novel coumarin analogues.

  2008cites this paper
• The role of neurogenesis in neurodegenerative diseases and its implications for therapeutic development.

  2008cites this paper
• Synthesis and structure-activity relationship studies of theophylline analogs on population responses in the rat hippocampus in vitro.

  2008cites this paper
• Drug therapy in Alzheimer disease: an update for the oral health care provider.

  2008cites this paper
• Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.

  2008cites this paper
• Dracocephalum moldavica L. and Melissa officinalis L.: Chemistry and Bioactivities Relevant in Alzheimer's Disease Therapy

  2008influential citation
• Memantine: potential and demonstrated effects of a new drug

  2008cites this paper
• Glutamate Receptor Antagonists and the Treatment of Neurological Disorders

  2008cites this paper
• Dissociation Between the Potent β-Amyloid Protein Pathway Inhibition and Cholinergic Actions of the Alzheimer Drug Candidates Phenserine and Cymserine

  2008cites this paper
• UNIVERSIDADE FEDERAL DE SANTA MARIA CENTRO DE CIÊNCIAS DA SAÚDE PROGRAMA DE PÓS-GRADUAÇÃO EM FARMACOLOGIA AÇÃO ANTIOXIDANTE E NEUROPROTETORA DE COMPOSTOS PIRAZOLÍNICOS INÉDITOS

  2008cites this paper
• Coenzyme Q10: A Review of Its Promise as a Neuroprotectant

  2007cites this paper
• Neuropathological and Immunochemical Studies of Brain Parenchyma in Acetylcholinesterase Knockout Mice: Implications in Alzheimer's Disease

  2007cites this paper
• The Aβcentric Pathway of Alzheimer’s Disease

  2007cites this paper
• Role of the APP non-amyloidogenic signaling pathway and targeting alpha-secretase as an alternative drug target for treatment of Alzheimer's disease.

  2007cites this paper
• Memantine: efficacy and safety in mild-to-severe Alzheimer’s disease

  2007cites this paper